Will American Tower Stock Recover?
The performance of the real estate investment trust, or REIT,…
Sell
26
CNTA Quote, Financials, Valuation and Earnings
Last price:
$16.62
Seasonality move
:
14.68%
Day range:
$16.77 - $18.00
52-week range:
$6.65 - $18.97
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.49x
Volume:
586.2K
Avg. volume:
618.1K
1-year change:
117.52%
Market cap:
$2.2B
Revenue:
$6.9M
EPS (TTM):
-$1.52
Analysts' Opinion
-
Consensus RatingCentessa Pharmaceuticals PLC has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $28.57, Centessa Pharmaceuticals PLC has an estimated upside of 67.97% from its current price of $17.01.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $24.00 representing -41.09% downside risk from its current price of $17.01.
Fair Value
-
According to the consensus of 6 analysts, Centessa Pharmaceuticals PLC has 67.97% upside to fair value with a price target of $28.57 per share.
CNTA vs. S&P 500
-
Over the past 5 trading days, Centessa Pharmaceuticals PLC has underperformed the S&P 500 by -0.98% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Centessa Pharmaceuticals PLC does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Centessa Pharmaceuticals PLC has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Centessa Pharmaceuticals PLC reported revenues of --.
Earnings Growth
-
Centessa Pharmaceuticals PLC has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Centessa Pharmaceuticals PLC reported earnings per share of -$0.37.
Enterprise value:
1.8B
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-13.81x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -$177.7M | -$161.7M | -$40.2M | -$46.4M | |
| EBITDA | -- | -$174.1M | -$147.2M | -$38.7M | -$39.2M | |
| Diluted EPS | -$2.54 | -$1.64 | -$1.52 | -$0.40 | -$0.37 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $611.6M | $477M | $332.5M | $568.4M | |
| Total Assets | -- | $612.2M | $479.4M | $377.4M | $609.7M | |
| Current Liabilities | -- | $29.1M | $38.2M | $35M | $26.4M | |
| Total Liabilities | -- | $63.1M | $106.4M | $118M | $110.6M | |
| Total Equity | -- | $549.1M | $372.9M | $259.4M | $499.1M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$180.9M | -$130.3M | -$37.4M | -$21.4M | |
| Cash From Investing | -- | -$109.2M | -$12M | $48.7M | $45M | |
| Cash From Financing | -- | $14.8M | $368.2M | $14.7M | $246M | |
| Free Cash Flow | -- | -$181.6M | -$130.4M | -$37.4M | -$21.4M | |
CNTA
Sector
Market Cap
$2.2B
$49.2M
Price % of 52-Week High
89.67%
48.57%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
117.52%
-30.94%
Beta (5-Year)
--
0.754
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$17.03
200-day SMA
Buy
Level
$12.76
Bollinger Bands (100)
Buy
Level
14.09 - 17.41
Chaikin Money Flow
Buy
Level
6.2M
20-day SMA
Sell
Level
$17.19
Relative Strength Index (RSI14)
Sell
Level
49.87
ADX Line
Sell
Level
18.18
Williams %R
Neutral
Level
-41.573
50-day SMA
Buy
Level
$16.77
MACD (12, 26)
Buy
Level
0.02
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
11.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.2929)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.
Stock Forecast FAQ
In the current month, CNTA has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CNTA average analyst price target in the past 3 months is $28.57.
-
Where Will Centessa Pharmaceuticals PLC Stock Be In 1 Year?
According to analysts, the consensus estimate is that Centessa Pharmaceuticals PLC share price will rise to $28.57 per share over the next 12 months.
-
What Do Analysts Say About Centessa Pharmaceuticals PLC?
Analysts are divided on their view about Centessa Pharmaceuticals PLC share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Centessa Pharmaceuticals PLC is a Sell and believe this share price will drop from its current level to $24.00.
-
What Is Centessa Pharmaceuticals PLC's Price Target?
The price target for Centessa Pharmaceuticals PLC over the next 1-year time period is forecast to be $28.57 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CNTA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Centessa Pharmaceuticals PLC is a Buy. 6 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CNTA?
You can purchase shares of Centessa Pharmaceuticals PLC via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Centessa Pharmaceuticals PLC shares.
-
What Is The Centessa Pharmaceuticals PLC Share Price Today?
Centessa Pharmaceuticals PLC was last trading at $16.62 per share. This represents the most recent stock quote for Centessa Pharmaceuticals PLC. Yesterday, Centessa Pharmaceuticals PLC closed at $17.01 per share.
-
How To Buy Centessa Pharmaceuticals PLC Stock Online?
In order to purchase Centessa Pharmaceuticals PLC stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Booking Holdings Stock Split?
Booking Holdings, the travel and technology company that owns brands…
Why Buy Domino’s Pizza Stock?
When you think of growth stocks, you probably imagine technology…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 121x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Buy
70
OKLO alert for Jan 6
Oklo [OKLO] is up 12.77% over the past day.
Sell
39
DOGZ alert for Jan 6
Dogness (International) [DOGZ] is down 1.64% over the past day.
Buy
66
DMRC alert for Jan 6
Digimarc [DMRC] is down 0.83% over the past day.
